# A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

> **NCT04100018** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1030 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Prednisone
- **DRUG:** Docetaxel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04100018
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-06
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-06-25
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04100018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04100018, "A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04100018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*